BIOGEN INC (BIIB) Stock Price, Quote, News and Overview
NASDAQ:BIIB - Nasdaq - US09062X1037 - Common Stock - Currency: USD
BIIB Quote, Performance and Key Statistics
BIOGEN INC
NASDAQ:BIIB (1/30/2025, 1:40:00 PM)
147.11
+2.7 (+1.87%)
The current stock price of BIIB is 147.11 USD. In the past month the price decreased by -4.56%. In the past year, price decreased by -40.75%.
BIIB Latest News, Press Releases and Analysis
Tuesday's session: top gainers and losers in the S&P500 index
Top S&P500 movers in Tuesday's session
Which S&P500 stocks are moving on Tuesday?
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
Gapping S&P500 stocks in Tuesday's session
Tuesday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail
The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.
BIIB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.35 | 310.61B | ||
| AMGN | AMGEN INC | 14.83 | 153.19B | ||
| GILD | GILEAD SCIENCES INC | 21.82 | 120.49B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 866.06 | 113.75B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.06 | 75.19B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.83B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.53B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.30B | ||
| NTRA | NATERA INC | N/A | 23.35B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.57B | ||
| MRNA | MODERNA INC | N/A | 16.08B |
Related stock screener links
About BIIB
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,570 full-time employees. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. The company also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. The company commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
Company Info
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Michel Vounatsos
Employees: 7570
Company Website: https://www.biogen.com/
Investor Relations: https://investors.biogen.com
Phone: 17814642000
BIIB FAQ
What is the stock price of BIIB?
The current stock price of BIIB is 147.11 USD.
What is the symbol for BIOGEN INC stock?
The exchange symbol of BIOGEN INC is BIIB and it is listed on the Nasdaq exchange.
On which exchange is BIIB stock listed?
BIIB stock is listed on the Nasdaq exchange.
Is BIIB a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for BIIB, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of BIIB.
Does BIIB stock pay dividends?
BIIB does not pay a dividend.
When does BIIB stock report earnings?
BIIB will report earnings on 2025-02-12, after the market close.
What is the Price/Earnings (PE) ratio of BIIB?
The PE ratio for BIIB is 9.01. This is based on the reported non-GAAP earnings per share of 16.33 and the current share price of 147.11 USD.
What is the Short Interest ratio of BIIB stock?
The outstanding short interest for BIIB is 2.54% of its float.
BIIB Technical Analysis
BIIB Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BIIB. BIIB scores excellent on profitability, but there are some minor concerns on its financial health.
BIIB Financial Highlights
Over the last trailing twelve months BIIB reported a non-GAAP Earnings per Share(EPS) of 16.33. The EPS decreased by 3.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.81% | ||
| ROA | 5.7% | ||
| ROE | 9.87% | ||
| Debt/Equity | 0.28 |
BIIB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to BIIB. The Buy consensus is the average rating of analysts ratings from 42 analysts.
For the next year, analysts expect an EPS growth of 10.84% and a revenue growth -2.86% for BIIB